- Home
- NMG vs CMPX Comparison
NMG vs CMPX Comparison
Compare NMG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- CMPX
- Stock Information
- Founded
- NMG 2011
- CMPX 2014
- Country
- NMG Canada
- CMPX United States
- Employees
- NMG N/A
- CMPX N/A
- Industry
- NMG Other Metals and Minerals
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- CMPX Health Care
- Exchange
- NMG Nasdaq
- CMPX Nasdaq
- Market Cap
- NMG 249.7M
- CMPX 291.8M
- IPO Year
- NMG 2017
- CMPX N/A
- Fundamental
- Price
- NMG $1.94
- CMPX $2.70
- Analyst Decision
- NMG Strong Buy
- CMPX Strong Buy
- Analyst Count
- NMG 2
- CMPX 9
- Target Price
- NMG $2.58
- CMPX $12.67
- AVG Volume (30 Days)
- NMG 185.0K
- CMPX 775.6K
- Earning Date
- NMG 08-18-2025
- CMPX 08-19-2025
- Dividend Yield
- NMG N/A
- CMPX N/A
- EPS Growth
- NMG N/A
- CMPX N/A
- EPS
- NMG N/A
- CMPX N/A
- Revenue
- NMG N/A
- CMPX $850,000.00
- Revenue This Year
- NMG N/A
- CMPX N/A
- Revenue Next Year
- NMG N/A
- CMPX N/A
- P/E Ratio
- NMG N/A
- CMPX N/A
- Revenue Growth
- NMG N/A
- CMPX N/A
- 52 Week Low
- NMG $1.22
- CMPX $0.98
- 52 Week High
- NMG $2.58
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- NMG 53.58
- CMPX 41.71
- Support Level
- NMG $1.89
- CMPX $2.80
- Resistance Level
- NMG $2.00
- CMPX $3.03
- Average True Range (ATR)
- NMG 0.11
- CMPX 0.19
- MACD
- NMG -0.01
- CMPX -0.07
- Stochastic Oscillator
- NMG 40.20
- CMPX 3.85
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.